Riverwater Partners, an investment management company, released its 'Small Cap Strategy' Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined by accelerating AI investment, energy market disruptions, and renewed investor appetite for higher-beta stocks, creating headwinds for the firm's quality-focused approach and healthcare positioning. Despite this, stock selection contributed positively in energy, materials, and financials, while healthcare and consumer discretionary detracted due to the fund's disciplined avoidance of speculative businesses. Looking ahead, the firm remains cautiously optimistic, focusing on opportunities created by market dislocations, including AI infrastructure enablers, select consumer companies, healthcare innovators, and energy businesses trading below intrinsic value. The strategy continues to emphasize high-quality companies with strong management teams and attractive valuations, positioning the portfolio for a potential rotation away from speculative market leadership. In addition, please check the Strategy's top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Riverwater Partners Small Cap Strategy highlighted LeMaitre Vascular, Inc. (NASDAQ:LMAT). LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a medical device company focusing on the manufacturing and development of products and services for vascular surgery. On August 31, 2026, LeMaitre Vascular, Inc. (NASDAQ:LMAT) closed at $80.28 per share.LeMaitre Vascular, Inc. (NASDAQ:LMAT) declined 24.11% in a month and 15.52% over the past 52 weeks. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has a market capitalization of $1.84 billion with a 52-week trading range between $78.27 - 118.01.
Riverwater Partners Small Cap Strategy stated the following regarding LeMaitre Vascular, Inc. (NASDAQ:LMAT) in its Q2 2026 investor letter:
"LeMaitre Vascular, Inc. (NASDAQ:LMAT), our peripheral vascular device holding, declined approximately 12% in a quarter when nearly everything profitable in small cap health care went down and nearly everything speculative went up. The company's niche leadership, pricing power, and consistent execution are unchanged, and we view the weakness as sentiment-driven rather than fundamental."
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held LeMaitre Vascular, Inc. (NASDAQ:LMAT) at the end of the second quarter which was 26 in the previous quarter. While we acknowledge the potential of LeMaitre Vascular, Inc. (NASDAQ:LMAT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI sto